At BIO Asia-Taiwan 2026, speakers framed in vivo CAR T as a second wave for scalable cell therapy durability while debating how best to deliver the therapeutic payload in patients. The focus on delivery technology reflects the field’s transition from feasibility demonstrations to repeatable, manufacturable clinical deployment. The coverage emphasizes that in vivo approaches could reduce complexity versus ex vivo manufacturing, but delivery remains a gating variable for tissue targeting, exposure control, and clinical durability. For the industry, the near-term practical question is whether delivery systems can achieve consistent pharmacology and safety across diverse patient populations, enabling broader clinical scaling beyond early proof-of-concept.